Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by iknownothingaloton May 13, 2016 2:06pm
242 Views
Post# 24871247

Some Observations

Some ObservationsLike Bill Ackman I should have been out of this stock and never come back. There has been a tremendous amount of technical damage to this share price that will take years to repair. Longer term shareholders must now align themselves with Ackman and his ability to repair the company and its stock price. First, understand that the significant volumes that we have seen to the downside the past week are not shorts (Chanos and his ilk can only short so many shares)many of those large investors who are not prepared to put more money in are rotating out of the stock putting downward pressure on the equity add to that some shorting and weak retail and you have the perfect scenario. Either way, a retest of the $25.32 low from March was inevitable, hopefully this will be the last test. For those expecting a quick rebound I suggest you review your expectations as it will take time to heal the wounds ( negative headlines are still overwhelming and will be for awhile) and it will take some time to truly determine Fair Value. At the end of the day my worst case scenario is a split of this company into three seperate listings as Tyco did a few years back.
<< Previous
Bullboard Posts
Next >>